TP53 and colorectal carcinoma: In a study comparing the immunostaining of p53 with the TP53 gene mutation, neither the IHC nor the sequencing alone have a full capability to predict p53 status; however, when combined, these two technologies provide a more complete assessment of p53 status in patients with CRC [69].